Cryoglobulinemia is a common extrahepatic manifestation of infection with hepatitis C virus (HCV). When signs and symptoms of systemic vasculitis or glomerulonephritis occur in the presence of circulating cryoglobulins, this syndrome is called "mixed cryoglobulinemia syndrome" (MCS). Historically, interferon-based therapies in HCV have been associated with lower rates of viral cure in patients with MCS than in the general HCV-infected population. The advent of direct-acting antiviral therapies have revolutionized the treatment of HCV, dramatically increasing rates of cure. Early studies of first-generation protease inhibitors (telaprevir and boceprevir) in combination with interferon and ribavirin demonstrated HCV cure rates of 67% and complete clinical response rates of vasculitis symptoms in 60% of patients with MCS; however, regimens were poorly tolerated by patients, 22% discontinued treatment early. More recently, all-oral, interferon-free regimens have become available and combination therapies are now being approved for patients with and without renal impairment. Patients with HCV-MCS achieved sustained virologic response in 297 out of 313 patients (95%) treated with direct-acting antiviral therapy, and 85% had a complete or partial clinical response of MCS symptoms. Current direct-acting antiviral therapies are well tolerated in patients with HCV-MCS and only 1.6% discontinued treatment early. Patients with cryoglobulinemic glomerulonephritis also had an excellent cure rate (94%). The majority improved; 17/52 (33%) experienced full remission and 15/52 (29%) experienced partial remission. There were no reports of worsening kidney function in patients treated with direct-acting antiviral therapies. Less than 5% of patients with HCV-MCS treated with IFN-free direct-acting antiviral therapy required immunosuppression. However, patients with severe vasculitis appear to still require concomitant immunosuppression.
INTRODUCTION
Cryoglobulinemia is a common extrahepatic manifestation of chronic hepatitis C virus (HCV) infection. [1] [2] [3] The term "cryoglobulin" refers to proteins that circulate in the serum, precipitate below core body temperature, and dissolve upon rewarming. 4, 5 HCV is associated with mixed cryoglobulinemia (types II and III) according to the Brouet classification system (Table 1) , and is the most common cause of mixed cryoglobulinemic syndrome (MCS).
infected patients, up to 50% with chronic HCV will have detectable serum cryoglobulins at some point during their infection, however only 2%-3% develop vasculitic symptoms that characterize HCV-MCS ( Figure 1 ). Cryoglobulinemia may occur with or without chronic liver disease, suggesting a pathogenic role of HCV in the development of MCS. [7] [8] [9] [10] [11] HCV RNA and anti-HCV antibodies are concentrated in cryoprecipitate, further supporting the pathogenic role of the virus itself. 12, 13 Common presentations of HCV-MCS include cutaneous vasculitis (palpable purpura), weakness, neuropathy, arthralgia, and hematuria and proteinuria due to cryoglobulinemic glomerulonephritis (CGN). Rheumatoid factor (RF) is significantly elevated in 45%-68% of cases and hypocomplementemia is present in 51%-76% of cases; both of these serological findings are most common in HCV-related cryoglobulinemia than in non-HCV-related cryoglobulinemia.
14-16 HCV-MCS is more common in women than in men, affects patients with cirrhosis more than those with chronic hepatitis and is unaffected by genotype or duration of HCV infection. 15 Until recent treatment advances, HCV-MCS was associated with 1-year, 3-year, 5-year, and 10-year survival rates of 96%, 86%, 75%, and 63%, respectively. 17 
CRYOGLOBULINEMIC GLOMERULONEPHRITIS
CGN occurs nearly exclusively with type-II cryoglobulinemia ( Figure 2) . 15 Typical renal manifestations include hypertension, proteinuria, microscopic hematuria, acute nephritis, or nephrotic syndrome. 18 Light microscopy shows a membranoproliferative pattern of injury due to deposition of mesangial and subendothelial immune complexes in renal tissue leading to glomerular hypercellularity, thickening of the glomerular basement membrane and a "double-contoured" appearance. 11, 19 Electron microscopy typically shows endocapillary proliferation and subendothelial deposits. 20 Immunofluorescence confirms mesangial and capillary wall deposition of IgM, IgG, and C3; subendothelial and intraluminal deposits have the same idiotype as circulating monoclonal IgM RF (Figure 2) . 21 Vasculitis of the small-and medium-sized renal arteries may be seen in approximately one-third with CGN. 20, 22 Large eosinophilic, intraglomerular deposits that stain positively with periodic acid-Schiff may fill the capillary lumen; these "pseudothrombi" are pathognomonic and are associated with a more rapidly progressive course. 22 Approximately, 20% have significant podocyte injury and these patients often present with nephrotic-range proteinuria. 20, [22] [23] [24] Milder forms of CGN, referred to as mesangioproliferative GN, are characterized by increase in the mesangial matrix without significant infiltration of leukocytes on biopsy. 22 These patients typically demonstrate mild urinary abnormalities and normal renal function.
OTHER GLOMERULAR DISEASES ASSOCIATED WITH CHRONIC HCV INFECTION
Membranous nephropathy is a less common renal manifestation of HCV. Unlike patients with membranoproliferative glomerulonephritis, these patients commonly present with nephrotic syndrome and typically have normal complement levels and no RF or cryoglobulinemia. 25, 26 Fibrillary glomerulonephritis and immunotactoid glomerulopathy have been associated with HCV infection; these diseases are characterized by organized immune deposits with mesangial and capillary wall fibrils measuring 16-24 and 32-50 nm, respectively. [27] [28] [29] [30] The clinical presentation of Fibrillary glomerulonephritis (FGN) and immunotactoid glomerulonephritis (ITGN) is typically nephrotic-range proteinuria, hematuria, hypertension, and acute or chronic renal insufficiency. Prognosis is poor in untreated patients. [31] [32] [33] Finally, IgA nephropathy is increased with all forms of cirrhosis, due to impaired clearance of IgA and IgA-containing immune complexes. This secondary form of IgA nephropathy ranges in severity, while it may cause significant hematuria and proteinuria and variable degrees of renal insufficiency, it is often clinically silent. Many cases of HCV-related GN are clinically silent and the true prevalence may be under-estimated by noninvasive testing such as serum creatinine and urinalysis. 35, 36 A study of 30 HCV-infected patients with end-stage liver disease undergoing liver transplant in the United States who had kidney biopsies intraoperatively showed that 25 (83%) had immune-complex GN. None of these patients had known cryoglobulinemia and 10/25 had normal urinalysis and creatinine levels at the time of transplant. 35 The high prevalence of clinically silent kidney disease at liver transplantation may explain the higher frequency of proteinuria and chronic kidney disease after liver transplant for HCV. [37] [38] [39] [40] A Japanese study of 188 autopsies conducted in adults with chronic HCV infection and known HCVrelated liver disease found that 45% had histological evidence of GN, yet only 12% had abnormal urinalysis. 36 Multivariate analysis showed that HCV-related GN correlated most strongly with the presence of esophageal varices (RR of 2.38). 36 Thus, even in patients without overt evidence of kidney disease, longstanding HCV infection leads to glomerular abnormalities in a substantial number.
TREATMENT OF HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME Antiviral therapy: Historical use of IFN and ribavirin in HCV-related MCS
The association between IFN and resolution of HCV-MCS was established in the earliest series of patients with CGN. Johnson et al. treated four patients with HCV-MCS and CGN with IFN-a monotherapy and all patients experienced a reduction in proteinuria. 12 Rossi et al. report three patients with CGN who were treated with PEG-IFN-a/RBV (ribavirin) for 12 months and achieved sustained virologic response (SVR) in addition to long-term clinical and histologic remission of CGN. Repeat kidney biopsies performed 14-26 months after the end of treatment showed marked reduction of glomerular inflammations and immune deposits with minimal residual glomerular lesions. 57 Most studies have shown that the benefit of IFN-based therapies is limited to patients who clear HCV RNA. Complete clinical response usually but not always correlates with SVR, which is synonymous with cure. 58, 59 However, IFN-based therapies are less likely to lead to SVR in patients with HCV-MCS than in the general HCV-infected population. 60 IFN-a monotherapy achieved SVR in 4%-27% of patients with HCV-MCS and a moderate complete clinical response rate of 27%-62%. 58, 59, [61] [62] [63] The combination of pegylated IFN-a with RBV is more efficacious, resulting in SVR rates of 18%-54% and complete clinical response rates of 44%-77%, although relapse rates are still as high as 60%, and because of this improvement in renal manifestations is only seen in 50%. 45, [63] [64] [65] [66] [67] Patients whose HCV relapses after IFN-based treatment typically have recurrence of HCV-MCS symptoms. Multiple studies have shown that longer courses of IFN therapy (at least 48 weeks) are beneficial for patients with HCV-MCS, however, it is extremely difficult to tolerate. 58, 68, 69 Little is known about the effect of IFN-based treatment on the other HCV-associated glomerular diseases. There are two case reports of patients with HCV-related IgA nephropathy who had resolution of proteinuria after treatment with IFN with or without RBV. 70, 71 There is also a case report of a patient with HCV and fibrillary glomerulonephritis who had an improvement in renal function following treatment with IFN. 27 
Addition of rituximab-based immunosuppression in patients treated with interferon-based antiviral therapies
The goals of treatment of HCV-MCS are to eradicate HCV infection and cure the symptoms of MCS. Antiviral therapy to eliminate the viral trigger is the cornerstone of management, however immunosuppression that targets the downstream B-cell arm of autoimmunity has historically been necessary to prevent disease progression given the poor efficacy of IFN-based therapy. The type of immunosuppression used typically depends on the severity of the disease presentation and includes the use of corticosteroids, cytotoxic agents, and/or plasmapheresis. Rituximab, an anti-CD20 monoclonal antibody, with or without corticosteroids is highly effective at decreasing the production of cryoglobulins and treating their clinical sequelae. [41] [42] [43] [44] Importantly, data suggests that rituximab did not reduce the efficacy of IFN-based antiviral therapy in achieving SVR. 45, 46 Complete clinical response may be seen in 54%-73%, although relapse rates may be as high as 39%. 45, 47, 48 Multiple prospective studies have shown that when rituximab was added to antiviral therapy it shortened the time to clinical remission, led to better renal response rates, and higher rates of cryoglobulin clearance. 45, 48, 49 Even when used in the absence of concurrent antiviral therapy, rituximab can improve clinical symptoms of HCV-MCS. 50, 51 The safety of rituximab in HCV-MCS and cirrhosis has been confirmed by multiple studies, which have shown no increase in HCV viremia and stable liver, function tests during rituximab therapy. [49] [50] [51] Thus, in the era of IFN-based therapy for HCV, guidelines recommended initiation of antiviral therapy and rituximab-based immunosuppression at the time of diagnosis of HCV-MCS, particularly in cases of CGN. 56 Rituximab-based immunosuppression can be given simultaneously with antiviral therapy.
It is important to note that in patients previously infected with hepatitis B virus (HBV), rituximab increases the risk of reactivation in both HBV surface antigen (HBsAg)-negative and HBsAg-positive patients. 52, 53 In patients treated with rituximab-containing chemotherapy, the risk of HBV reactivation is elevated at 14%-72% (without antiviral prophylaxis) but it is believed that rituximab monotherapy for rheumatologic indications carries a much lower risk of reactivation, although the exact risk is unknown.
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OVERVIEW OF DIRECT-ACTING ANTIVIRAL THERAPIES FOR HCV
Direct-acting antivirals (DAAs) are molecules that target the nonstructural proteins of HCV, resulting in disruption of viral replication. The three approved classes of DAAs include inhibitors of NS3/4A protease, NS5A protein, and NS5B polymerase. The general approach for curative treatment is to target multiple components of the virus with agents from two or more classes, and inhibit them for 8-24 weeks; this is sufficient to achieve cure in the vast majority (95%). Treatment duration is generally determined by the potency of the regimen, genotype, and whether the patient has cirrhosis or prior HCV treatment experience. 72 First-generation NS3/4A protease inhibitors, telaprevir and boceprevir, were approved for the treatment in HCV in combination with IFN/RBV in 2011. Though teleprevir and boceprevir increased treatment success, these drugs were also very poorly tolerated, and relied on concomitant IFN/RBV use (Table 2a ). In 2013, sofosbuvir was the first novel DAA approved by the FDA, which revolutionized the management of HCV. Now, IFN-free combination therapies are the standard of care for all patients with HCV (Table 2b) . Rates of SVR vary by HCV genotype, but are upwards of 95% for all genotypes. 60, 73 DAAs are very welltolerated with rates of serious adverse events (SAEs) of less than 10% (less than 1% for some regimens) and early discontinuation rates of less than 3%. 74 In the last year, "pangenotypic" therapies that effectively function against the major viral genotypes 1-6 have been approved by the FDA. 75, 76 Now even the small minority of patients who fail first-line DAA regimens can be successfully retreated with combinations of newer, more potent agents.
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DAA THERAPY IN PATIENTS WITH IMPAIRED RENAL FUNCTION
All of the approved DAA regimens can be used in patients with estimated glomerular filtration rate (eGFR) >30 mL/ min/1.73 m 2 and the appropriate regimen should be selected based on HCV genotype, presence, or absence of cirrhosis and HIV co-infection. All regimens may be used in HCV-infected patients with suspected glomerulonephritis and subnephrotic proteinuria. There are three regimens approved for patients with eGFR <30 mL/min/ 1.73 m 2 or on dialysis. These include (1) paritaprevir/ritonavir/ombitasvir and dasabuvir, (2) elbasvir and grazoprevir, or (3) glecaprevir and pibrentasvir (Tables 3 and  4) . 56, 76, 79, 80 While multiple studies have shown that sofosbuvir-based therapies are effective in patients with eGFR <30 mL/min/1.73 m 2 , its active metabolite GS-331007 accumulates in renal failure and sofosbuvir is not approved for patients with eGFR < 30 mL/min/1.73 m 2 81-84 In patients with HCV-MCS who present with nephrotic syndrome, a biopsy should be undertaken before initiation of antiviral therapy (choice of DAA regimen depends on eGFR), rituximab, and steroid therapy. In the small minority of patients who present with rapidly progressive glomerulonephritis (RPGN), treatment with urgent plasma exchange, IV methylprednisone, and rituximab should be initiated. Again, DAA therapy should be selected based on the eGFR; there is no specific preferred DAA regimen in cases of RPGN or nephrotic syndrome (Table 4) . Dialysis patients with HCV-MCS should be treated to manage nonrenal manifestations of MCS.
DIRECT-ACTING ANTIVIRAL TREATMENT IN MIXED CRYOGLOBULINEMIA SYNDROME
IFN-containing DAA regimens
Teleprevir or boceprevir (first generation protease inhibitors) increased HCV cure rates in patients with HCV-MCS, but because they were paired with IFN and RBV, they were difficult to tolerate and led to a large number of discontinuations. Saadoun et al. treated 30 HCV-MCS patients with a telaprevir or boceprevir-based regimen and 20/30 (67%) achieved SVR. Fourteen of the 20 who achieved SVR (70%) had a complete clinical response at 72 weeks. However, 6/10 (60%) of those who did not achieve Rutledge et al.
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Hemodialysis International 2018; 22:S81-S96 (1) SIM1DAC (2) SOF1DAC (1) ASV1DAC1IFN1RBV (2) ND5/7 (71%)7/7 (100%)2/7 (29%) SVR also had a complete clinical response, likely because approximately half of the overall cohort received concomitant immunosuppression. During follow-up, two clinical relapses of vasculitis were observed in the nonvirologic responders. Of the seven cases with nephropathy, remission was noted in 5/7. Four out of these seven patients were treated with rituximab. Overall, first generation protease inhibitor-based treatments were not well tolerated; nearly half of the cohort experienced SAEs and 93% required erythropoietin stimulating agents to treat anemia as a result of RBV. 46 Others series using teleprevir or boceprevir report varying results, notably Gragnani et al. treated five patients with HCV-MCS with boceprevir-based therapy, none of these patients achieved SVR, nor did any achieve a clinical response. 85 Overall, telaprevir or boceprevir-based therapies achieved SVR in 35/52 patients (67%), though these have now been replaced by newer, more effective IFN-free DAA regimens which are much better tolerated.
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IFN-free DAA regimens
Several centers have published their experience with novel DAA therapies in HCV-MCS, including agents such as sofosbuvir, simeprevir, daclatasvir, ledipasvir, asunaprevir, dasabuvir, pariteprevir, and ombitasvir (Table 2) . Studies demonstrate that DAA regimens achieve SVR in 95% (297 out of 313) of patients with HCV-MCS, which is similar to cure rates in the general population with HCV. [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] There are currently no reports of HCV-MCS treated with more recently approved DAAs, such as sofosbuvir/velpatasvir/voxilaprevir, elbasvir/grazoprevir, glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir, but there is no reason to think that these agents would be less effective in HCV-MCS.
The complete clinical remission rate of HCV-MCS symptoms after IFN-free DAA therapy ranged widely between studies but across all studies, 85% of patients were reported to have either a partial (20%) or complete clinical response (65%). [87] [88] [89] [90] [91] [92] [93] 99 Achieving clinical remission was tied to SVR status, but there were several cases of complete clinical response in patients who relapsed virologically. 46, [85] [86] [87] [88] [89] [90] 95, 98 Overall, 54% of DAA-treated patients with SVR had a complete clinical response (defined as improvement or resolution of all the baseline vasculitis symptoms and lack of clinical relapse). Symptoms such as myalgia, arthralgia, purpura, and skin ulcers were the most likely to respond with typical response rates of 75%-100% and often a rapid improvement in skin manifestations. Peripheral neuropathy and renal manifestations had lower rates of complete resolution (ranging from 30% to 70%). [87] [88] [89] 91 
DAA therapy in HCV-MCS with renal involvement
Renal involvement affects less than half of patients with HCV-MCS and each published series included a handful of patients with CGN, summarized in Table 3 . Saadoun et al. included five patients with CGN treated with sofosbuvir and RBV for 24 weeks; 4/5 showed improvement in eGFR and proteinuria. Gragnani et al. studied sofosbuvir-based DAA therapy in four patients with renal involvement. One had a biopsy-proven membranoproliferative glomerulonephritis (MPGN), one had nephrotic syndrome, two had proteinuria with reduced eGFR; all improved despite the fact that only one patients received immunosuppression with rituximab. 95 Sise et al. demonstrated that 4/7 patients with renal involvement who were treated with sofosbuvir-based therapy had an improvement in proteinuria and/or eGFR. Two of the four patients were treated with concurrent immunosuppression and 3/4 achieved SVR; one patient improved despite virologic relapse. 96 In a later study by Saadoun et al., 5 patients with renal involvement (four with renal biopsies showing MPGN) underwent treatment with sofosbuvir and daclatasvir. Renal manifestations improved in all and four had a complete remission of renal disease. Emery et al. included four patients with fulminant HCV-MCS vasculitis and rapidly progressive CGN. One had a complete renal response to treatment, two had partial responses (minimal proteinuria and hematuria but elevations in creatinine persisted) and one had no response. Two of these patients required dialysis on admission but after DAA treatment none required dialysis. All four patients with fulminant vasculitis and rapidly progressive CGN had also been treated with rescue therapy prior to DAA (rituximab and plasmapheresis in three and prednisone with plasmapheresis in one). In summary, of nine studies that evaluated response of GN to treatment with DAA, 17/52 patients (33%) showed complete resolution of GN and 15/52 (29%) showed improvement in renal parameters (Table 3) . Importantly, there are no reports that describe and adverse kidney events of DAAs, even in those who included patients who received sofosbuvir with creatinine clearance less than 30 mL/min/ 1.73 m 2 . 87, 96 There is currently no data that exists describing the renal response of other forms of HCVrelated glomerular diseases to DAA therapy.
Clinical response of HCV-MCS to DAA therapy
DAA therapy leads to a higher clinical remission of HCV-MCS than IFN-based therapies because of its significantly higher likelihood of leading to SVR; however, with IFNbased therapy, there is a closer correlation between SVR and clinical response. 99 SVR after IFN-based therapy leads to clinical remission in 88%-97% of patients who are cured of the virus. 58, 59, [100] [101] [102] The discrepancy between IFN-and DAA-treated patients may be explained by the longer treatment courses with IFN, thus at the time of SVR measurement, patients had been virus-free for longer and were more likely to have clinically responded. Additionally, it is possible that many patients treated with DAA-based therapy had failed prior rounds of IFN-based therapy and thus had HCV-MCS for an extended period of time prior to being cured. Finally, the immunomodulatory effects of IFN may also suppress clonal proliferation of B cells which drives cryoglobulin production, independently of the viral trigger. 101 Immunologic response of HCV-MCS to DAA therapy Fifteen studies reported changes in cryoglobulin levels (Table 2) ; overall 38% of subjects had complete disappearance of serum cryoglobulins and an additional 17% experienced a decrease in cryoglobulins. 46, [85] [86] [87] [88] [89] [91] [92] [93] [94] [95] [96] [97] [98] [99] 103 In the five studies that reported RF levels, RF normalized in 8/28 patients (two studies) and two other studies reported a significant decrease in the median RF titer. 88, 89, [94] [95] [96] Three studies report normalization of C4 levels in 20/41 patients (49%) and 3 of 4 other studies reported increase in average serum C4 levels.. 46, 88, 89, 92, [94] [95] [96] Though numbers are small and reporting of immunologic changes with DAAs varies, it seems that approximately half of patients with HCV-MCS experience normalization of the cryoglobulin level or complement level despite the fact that the virus is eliminated in a much higher portion (95%) (Figure 3 ).
Relationship between immunologic and clinical response of HCV-MCS to DAA therapy
The link between cryoglobulin decline and clinical response is less clear in DAA treated patients than in the IFN-treated population, of whom nearly all clinical responders had disappearance of cryoglobulins. 58, 59 In some recent series of patients treated with DAAs, clearance of cryoglobulins lagged substantially behind viral clearance and clearance of cryoglobulins did not necessarily ensure complete resolution of clinical symptoms. 86 immunological response. 89 Long-term studies are needed to determine if patients who achieve SVR with DAAs eventually achieve clinical and immunological regression with longer follow-up.
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Management of HCV-MC with severe vasculitis
In one study, 6/7 patients with severe vasculitis (defined as renal involvement, neurological symptoms with severe functional impairment, or requiring hospitalization for any symptom) achieved SVR but only one (17%) had a complete clinical response. All four patients with fulminant MCS (defined as severe vasculitis with rapidly progressive GN or multiorgan involvement) achieved SVR but none had a complete clinical response at last followup, although all had some clinical improvement. 87 This reflects the difficulty in entirely curing symptoms when manifestations of HCV-MCS are severe. With newer generation DAAs, the percentage of patients that received concomitant immunosuppression in clinical reports appears to be falling. Forty-three percent of patients treated with first generation protease inhibitors required rituximab or glucocorticoids, compared to 17% of patients treated with sofosbuvir and RBV. 46, 92 In more recent studies of sofosbuvir-based therapy, only 4.5%-4.8% of patients also required rituximab or corticosteroids. 88, 91 In a study by Bonacci et al., immunosuppressive therapy was reduced for 4/13 patients and withdrawn for 6/13. 89 However, it appears clear that patients with fulminant vasculitis are likely to require rescue immunosuppression prior or during DAA therapy and may remain dependent on immunosuppression despite achieving SVR. 87 Adverse events during DAA treatment Finally, SAEs were rare in patients receiving DAA regimens (Table 2) . Across all studies using IFN-free DAAs, the weighted average for SAEs was 3%, compared to 40% in those who received first-generation protease inhibitors (teleprevir or boceprevir) with IFN and RBV. The most common SAE reported was anemia in the setting of RBV use with DAA, and when RBVcontaining DAA studies are excluded, there were no SAEs reported in 77 patients. Overall, only 3/192 (1.6%) patients treated with IFN-free DAAs discontinued treatment early. [88] [89] [90] 92, 95, 96 Figure 3 Hepatitis C virus and targets for direct-acting antiviral therapy. Figure 4 Schematic representation of virologic, clinical, and immunologic outcomes for patients with HCV-MCS who are treated with DAAs. Approximately 95% will achieve SVR and be cured of HCV. Approximately 50% will achieve a full clinical response and 50% will achieve a full immunologic response. There is some, but not complete overlap between immunologic and clinical response. Many of the remaining patients will experience a partial clinical response and improvement but not complete normalization of immunologic abnormalities induced by HCV-MCS. A small number of DAA failures will experience clinical and immunologic response despite viral relapse. DAA 5 direct acting antiviral; HCV 5 hepatitis C virus; MCS5 5 mixed cryoglobulinemia syndrome; SVR 5 sustained virologic response.
CONCLUSION
MCS and CGN are important co-morbidities in patients with HCV infection. Eradication of HCV is the cornerstone of management of this syndrome. While cure rates for HCV were historically much lower in patients with HCV-MCS treated with IFN-based regimens compared to the general HCV-infected population, it has now been clearly demonstrated that DAAs are equally effective in patients with HCV-MCS as they are in the general population, curing 95% who are treated. There are effective IFN-free DAA regimens for HCV-infected patients with all genotypes and all levels of renal impairment (Table 4) . Immunosuppression is now only recommended for the minority of patients with HCV-MCS who have aggressive vasculitis symptoms at presentation. While the early results of treatment of patients with HCV-MCS with DAAs is promising, larger studies will be needed to determine which patients are likely to achieve a complete clinical remission and to devise strategies for those who relapse.
